相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacogenetic Pathway Analysis of Docetaxel Elimination
S. D. Baker et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
In vitro evidence for the role of OATP and OCT uptake transporters in drug-drug interactions
Juergen Kindla et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2009)
Gene-environment interactions in asthma
Erika von Mutius
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)
HLA-B☆5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
Ann K. Daly et al.
NATURE GENETICS (2009)
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types
Thorunn Rafnar et al.
NATURE GENETICS (2009)
Cytochrome P-450 Polymorphisms and Response to Clopidogrel.
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Genetic ancestry modifies pharmacogenetic gene-gene interaction for asthma
Harriet Corvol et al.
PHARMACOGENETICS AND GENOMICS (2009)
CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population
P. Borgiani et al.
PHARMACOGENOMICS (2009)
EGFR-targeted therapies in lung cancer: predictors of response and toxicity
Rebecca Suk Heist et al.
PHARMACOGENOMICS (2009)
Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions
M. R. Nelson et al.
PHARMACOGENOMICS JOURNAL (2009)
Pharmacogenomic progress in individualized dosing of key drugs for cancer patients
Christine M. Walko et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2009)
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
Ulrich M. Zanger et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2008)
CYP4F2 genetic variant alters required warfarin dose
Michael D. Caldwell et al.
BLOOD (2008)
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose
Gregory M. Cooper et al.
BLOOD (2008)
Effect of environmental substances on the activity of arylamine N-acetyltransferases
Fernando Rodrigues-Lima et al.
CURRENT DRUG METABOLISM (2008)
Clinical Pharmacogenetics and Potential Application in Personalized Medicine
Shu-Feng Zhou et al.
CURRENT DRUG METABOLISM (2008)
CYP450 pharmacogenetics for personalizing cancer therapy
Ron H.N. van Schaik
DRUG RESISTANCE UPDATES (2008)
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
Bryan P. Schneider et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Multiple loci identified in a genome-wide association study of prostate cancer
Gilles Thomas et al.
NATURE GENETICS (2008)
Multiple newly identified loci associated with prostate cancer susceptibility
Rosalind A. Eeles et al.
NATURE GENETICS (2008)
SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study
NEW ENGLAND JOURNAL OF MEDICINE (2008)
PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics
Bin Zhang et al.
PHARMACOGENOMICS (2008)
Cytochrome P450 3A polymorphisms and immunosuppressive drugs:: an update
Dany Anglicheau et al.
PHARMACOGENOMICS (2007)
CAR and PXR: The xenobiotic-sensing receptors
Yoav E. Timsit et al.
STEROIDS (2007)
The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity
Daniel Kurnik et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism:: Implication for optimization of breast cancer treatment
Silvana Borges et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy
A Ruzzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS) - novel predictors for response and survival in gastric cancer patients
E Goekkurt et al.
BRITISH JOURNAL OF CANCER (2006)
The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity:: Pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil
LK Mattison et al.
CLINICAL CANCER RESEARCH (2006)
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
F Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy
W Zhou et al.
CLINICAL CANCER RESEARCH (2004)
Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity:: A molecular and clinical study of 75 patients
E Rouits et al.
CLINICAL CANCER RESEARCH (2004)
XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy
S Gurubhagavatula et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer
WL Dahut et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Genetic basis of atherosclerosis: Part II - Clinical implications
AJ Lusis et al.
CIRCULATION (2004)
Epistasis: what it means, what it doesn't mean, and statistical methods to detect it in humans
HJ Cordell
HUMAN MOLECULAR GENETICS (2002)
分享论文
